Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia
- 25 March 2019
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 20 (8) , 917-928
Abstract
Introduction: Cardiovascular disease is a major cause of morbidity and mortality throughout the world and hypercholesterolemia is one of the key risk factors. Statins are the first line treatment to reduce atherogenic lipids and there is substantial and robust evidence with atorvastatin for reduction of cardiovascular events and mortality. Ezetimibe can be combined with any dose of atorvastatin for incremental lipid-lowering effects. Areas covered: In this review, the authors summarize the pharmacokinetics, pharmacodynamics and clinical efficacy of the components and the combination of ezetimibe and atorvastatin. Clinical benefits have been seen with ezetimibe combined with simvastatin but studies of its combination with atorvastatin are generally limited to the effects on lipid parameters where the addition of ezetimibe to atorvastatin is generally more effective than titrating the atorvastatin dose. Expert opinion: Although there are no cardiovascular outcomes studies with the combination of ezetimibe and atorvastatin, the greater reduction in atherogenic lipids can be assumed to have greater benefits in reducing cardiovascular events. The ezetimibe–atorvastatin combination is very effective in this respect and well tolerated. Fixed-dose combinations improve medication adherence and this combination should be useful for patients who cannot reach their lipid targets with maximally tolerated statin doses.Keywords
This publication has 89 references indexed in Scilit:
- Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)Journal of Lipid Research, 2012
- Effect of Two Intensive Statin Regimens on Progression of Coronary DiseaseNew England Journal of Medicine, 2011
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011
- Predictors of Nonadherence to Statins: A Systematic Review and Meta-AnalysisAnnals of Pharmacotherapy, 2010
- Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER DatabaseJournal of Lipid Research, 2010
- Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderlyJournal of Lipid Research, 2010
- Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and SimvastatinThe Journal of Clinical Endocrinology & Metabolism, 2010
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 DiabetesJACC, 2008
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995